【活動訊息-IFMAD 】(延長徵稿至4/6) 114/6/4-6/6 Discover Day 1 at IFMAD 2025: Fresh Approaches to Mood Disorder Treatment
轉知以下IFMAD活動資訊，歡迎參閱，如有任何相關疑問，請直接洽詢主辦單位，謝謝您。
Great news! The Early Bird deadline has been extended - register by 6th March 2025 to take advantage of reduced rates. Don’t miss this chance to secure your spot!
IFMAD 2025
Uncover Day 2’s Breakthrough Science in Budapest!
Come to Budapest for the 20th International Forum on Mood and Anxiety Disorders (IFMAD), where leading experts from around the world will discuss the latest breakthroughs in psychiatric care. Below, we highlight the Day 2 Scientific Programme - a deep exploration of groundbreaking research and clinical advancements!
We are pleased to inform you that the abstract submission deadline for IFMAD 2025 will be extended to April 6, 2025. This gives interested participants extra time to submit their research on Mood and Anxiety Disorders and participate in this exciting opportunity to present their work. We kindly ask you to circulate this important update within your networks, especially among junior professionals who may benefit from this extension.
Day 2 Highlights: Key Sessions & Speakers
Mortality in patients with major depressive disorder (MDD)
István Bitter (Hungary)
Key Insights:
A nationwide cohort study with an 11-year follow-up.
At 20 and 45, MDD patients had 7.8 and 6.0 years shorter life expectancy than that of controls, respectively.
MDD patients with somatic comorbidities or who converted to bipolar (6.8%) or schizophrenia (3.4%) had worse survival.
Takeaway: MDD is a leading cause of early death. Early detection and personalized treatment may lower mortality.
Guidelines for Anxiety Disorder, OCD and PTSD
Borwin Bandelow (Germany)
Key Insights:
For the 3rd edition of the World Federation of Societies for Biological Psychiatry guideline, 33 experts from 22 countries reviewed treatments for anxiety disorders, OCD, and PTSD in adults and children.
A total of 1007 RCTs were evaluated using the same rigorous methods for medications, psychotherapy, and other treatments.
Takeaway: SSRIs, SNRIs and CBT are the recommended treatment options for these disorders, but many other treatment modalities exist.
